Apollo Therapeutics
Cambridge
About Apollo Therapeutics
Apollo Therapeutics is a collaborative venture between three UK universities (Imperial College London, University College London, and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best British academic research, accelerating them towards the clinic. Apollo’s unique model provides quick, independent access to the resources to grow innovations and champion the best British academic research to industry. Apollo’s experienced team of industry scientists has a proven track record of therapeutic delivery and works in partnership with academics and industry partners, crafting each bespoke project to optimize the chances of long-term success. Apollo Therapeutics aims to create future therapies by partnering with the UK’s globally leading academic science base and UK-based Pharma industry to have a real impact on patient treatments and outcomes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $397.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2024)
- Website: apollotherapeutics.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/apollo-therapeutics-79500 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.